<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&lt;strong&gt;***Please note changes to the following:&lt;/strong&gt;&lt;/p&gt;&lt;ol&gt;&lt;li&gt;&lt;strong&gt;On both days, the meeting will begin at 7:45 a.m.&lt;/strong&gt;&lt;/li&gt;&lt;li&gt;&lt;strong&gt;On July 14th, the Open Public Hearing will be held from approximately 9:40 a.m. &amp;ndash; 10:40 a.m. ***&lt;/strong&gt;&lt;/li&gt;&lt;/ol&gt;&lt;table id="schedule" cellspacing="0" cellpadding="2" summary="This table shows the date, time, and location of the meeting" border="0" style="width: 643px; height: 93px"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a1" valign="top" align="left" bgcolor="#cccccc" style="width: 71px"&gt;Center&lt;/th&gt;&lt;th id="a2" valign="top" align="left" bgcolor="#cccccc" style="width: 158px"&gt;Date&lt;/th&gt;&lt;th id="a3" valign="top" align="left" bgcolor="#cccccc" style="width: 172px"&gt;Time&lt;/th&gt;&lt;th id="a4" valign="top" align="left" bgcolor="#cccccc" style="width: 238px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" headers="a1" style="width: 71px; height: 74px"&gt;CDER&lt;/td&gt;&lt;td valign="top" headers="a2" style="width: 158px; height: 74px"&gt;July 13-14, 2010&lt;br /&gt;&amp;nbsp;&lt;/td&gt;&lt;td valign="top" headers="a3" style="width: 172px; height: 74px"&gt;7:45 a.m. to 6:00 p.m.&lt;br /&gt;7:45 a.m. to 5:00 p.m.&lt;/td&gt;&lt;td valign="top" headers="a4" style="width: 238px; height: 75px"&gt;Hilton Hotel&lt;br /&gt;Washington DC North/Gaithersburg&lt;br /&gt;620 Perry Parkway&lt;br /&gt;Gaithersburg, Maryland&lt;br /&gt;Telephone: (301) 977-8900&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h4&gt;Agenda&lt;/h4&gt;&lt;p&gt;On both days, the committees will focus primarily on the cardiovascular safety of AVANDIA (rosiglitazone maleate) Tablets, GlaxoSmithKline, a drug approved for blood glucose control in adults with type 2 diabetes mellitus. Data specific to rosiglitazone to be presented will include results from the Rosiglitazone Evaluated for Cardiac Outcome and Regulation of Glycemia in Diabetes (RECORD) Trial, observational data, health claims data, and a meta-analysis of controlled clinical trials. In addition, the FDA will present its meta-analysis of several trials of ACTOS (pioglitazone hydrochloride) Tablets, Takeda Pharmaceuticals North America, Inc., another thiazolidinedione for the same indication, in response to public documents comparing the safety of rosiglitazone to pioglitazone based on different meta-analyses performed on each of these two drugs.&lt;/p&gt;&lt;h4&gt;Meeting Materials&lt;/h4&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&amp;nbsp;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href="[!--$wcmUrl('link','ucm191113.htm')--]"&gt;Background Material&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h4&gt;Public Participation Information&lt;/h4&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul class="noindent"&gt;&lt;li&gt;Written submissions may be made to the contact person on or before June 28, 2010.&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 9:40 a.m. to 10:40 a.m. on July 14, 2010. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before June 18, 2010&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by June 21, 2010.&lt;/p&gt;&lt;h4&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h4&gt;&lt;ul sizset="26" sizcache="1"&gt;&lt;li sizset="26" sizcache="1"&gt;Paul T. Tran, R.Ph., c/o Melanie Whelan&lt;br /&gt;Food and Drug Administration&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;WO51-6100&lt;br /&gt;Silver Spring, MD 20993-0002&lt;br /&gt;Phone: 301-796-9001&lt;br /&gt;Fax: 301&amp;ndash;847&amp;ndash;8737&lt;br /&gt;E-mail: &lt;a href="mailto:Paul.Tran@fda.hhs.gov"&gt;Paul.Tran@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area)&lt;br /&gt;Code: 3014512536 or 3014512535&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Website and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Paul Tran at (301) 796-9001 at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings.&lt;/p&gt;&lt;p sizset="27" sizcache="1"&gt;Please visit our Web site &lt;a href="[!--$wcmUrl('link','ucm111462.htm')--]"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
